

美時公告 9 月自結合併營收再度超越新台幣 10 億元，連續 7 個月年增成長
累計第 3 季自結合併營收逾新台幣 28 億元，再創今年單季新高

*Lotus Reported Unaudited September Revenues of NT\$1,021 Million, Delivering The 7th
Consecutive YoY Growth for Monthly Sales*

*The Company Also Concluded Its Q3'20 with Another Record High Quarterly Figures of Over
NT\$2.8 Billion in 2020*

2020 年 10 月 12 日，台北

October 12th, 2020, Taipei

特殊學名藥廠美時化學製藥（以下簡稱“美時”，台灣證券交易所股票代碼：1795）公佈 2020 年 9 月自結合併營收達新台幣 1,020,621 仟元，較去年同期成長逾 67%、再度超越新台幣 10 億元大關，並為今年以來連續第 7 個月營收繳出亮眼的年增成長。

美時表示本月亞太區域市場與外銷業務皆穩定發展，不僅在台灣市場如期上市其獨家代理之帕金森氏症原廠藥 Stalevo 及 Comtan、將帶動旗下中樞神經用藥產品組合之成長動能，而以外銷市場為主的抗癌用藥銷貨收入亦持續貢獻。其中，自有研發之重磅產品血癌用藥 Lenalidomide 順利地於 9 月下旬取得美國 FDA 暫定審查核可通知，不僅成為美國市場中第一個通過美國 FDA 審查核可的學名藥廠，並使得美時確定將可依照與原廠和解之條件、在 2022 年以限制出貨量的方式在美國搶進首波上市先機，大幅提升美時在全球癌症用藥領域之競爭優勢與核心地位。

Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795) today announced that its consolidated sales for September 2020 was NT\$1,020,621 thousand, representing more than 67% increase over the same period last year. This is also the seventh month in a row delivering robust YoY sales growth throughout the year.

Both Asian Business and Export Business continue to evolve stably – further to the first launch in Korea last month, the Company also launched the proprietary products Stalevo and Comtan, indicated for the treatment of Parkinson’s disease, in Taiwan in September to boost the overall momentum of its CNS portfolio. Supply revenue from export of oncology products also continues to contribute as the Company further extends the products to more addressable markets. In addition, Lotus received a tentative approval for the ANDA of its next blockbuster product, Lenalidomide, from US FDA in late September as expected. This is not only an affirmation for Lotus being able to launch the product as per its settlement agreement with the originator in the US in 2022, but also the first ever approval for the generic version of Revlimid® in the US, which strongly demonstrate Lotus’ core competence as the global preferred partner in oral oncology

第三季自結合併營收則再次創下今年新高，達新台幣 2,885,447 仟元，較去年同期大幅成長 46%、亦較前一季增加近 8%。而今年前 9 個月合併營收累計已近新台幣 76 億元，亦較去年同期增長超過 25%，年增成長強勁。

Lotus concluded Q3'20 with another record high quarterly sales of NT\$2,885,447 thousand in 2020, representing a 46% growth compared to the same period last year and around 8% increase over last quarter. Lotus has delivered an outstanding performance with YTD'20 consolidated sales of almost NT\$7.6 billion, achieving another 25% YoY growth.

新聞聯繫人 Contact:

美時製藥 投資人關係處長 樂君儀 (02)2700 5908 investor@lotuspharm.com

Angela Luan, Investor Relations Director

關於美時：

美時化學製藥股份有限公司（股票代碼：1795）成立於 1966 年，為一以台灣為基地供應全球市場之學名藥廠，高價值產品線涵蓋中樞神經系統、心血管疾病、癌症、女性保健、減肥等，並以錠劑、膠囊及軟膠囊劑型為主；美時自 2014 年成為艾威群集團的一員，現專注於快速成長的抗癌市場，並矢志透過整合台灣與韓國首屈一指的研發平台與其製造優勢嘉惠病患、員工與股東。美時的行銷與業務通路包含直營的亞洲市場及艾威群集團橫跨全球超過 30 個國家的商業網絡，此外，美時亦積極與一線藥廠就產品線策略結盟，是少數能進軍所有市場的新興藥廠。

About Lotus

Founded in 1966, Lotus is a generic company headquartered in Taiwan with high-value generic products covering CNS, CVS, oncology, women health, and anti-obesity drugs in tablets & hard/softgel capsule for global markets. It became an Alvogen Company in 2014. The primary focus of Lotus is on addressing the fast-growing oncology market. By aligning the company's internal development and manufacturing capabilities, Lotus aims to benefit patients, its employees and shareholders alike. The company boasts a best in class R&D and manufacturing platform across Taiwan and Korea. Further, Lotus can reach nearly every global market with its high value pipeline through the company's direct markets, relationship with Alvogen's commercial units spanning over 30 countries, and through alliances with top-tier pharma companies.

聲明：

本文件及同時發佈之相關資訊內含有預測性敘述。除針對已發生事實，所有對美時製藥(以下簡稱本

公司)未來經營業務、可能發生之事件及展望(包括但不限於預測、目標、估算和營運計劃)之敘述皆屬預測性敘述。預測性敘述會受不同因素及不確定性的影響,造成與實際情況有相當差異,這些因素包括但不限於價格波動、實際需求、匯率變動、市占率、市場競爭情況,法律、金融及法規架構的改變、國際經濟暨金融市場情勢、政治風險、成本估計等,及其他本公司控制範圍以外的風險與變數。這些預測性敘述是基於現況的預測和評估,本公司不負日後更新之責。